AstraZeneca and Orca partner to develop inhibitors for autoimmune diseases

Orca Pharmaceuticals has signed a three-year collaboration agreement with AstraZeneca to develop inhibitors of retinoic acid-related orphan nuclear receptor gamma (ROR γ).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news